Novartis will present data that highlight advancements in targeted combination therapy research, and underscore the company's continued commitment to bringing innovative treatments to patients living with advanced breast cancer at the 2015 CTRC-AACR San Antonio Breast Cancer Symposium (SABCS), December 8-12. Novartis will present 55 abstracts showcasing key real-world data from Afinitor® (everolimus), Tykerb® (lapatinib) and several investigational compounds in advanced breast cancer.
Because BKM120 (buparlisib), LEE011 (ribociclib), BYL719 (alpelisib) and LA-EP2006 are investigational compounds, the safety and efficacy profiles have not yet been fully established. Access to these investigational compounds is available only through carefully controlled and monitored clinical trials. These trials are designed to better understand the potential benefits and risks of the compound. Because of the uncertainty of the outcome/results of the clinical trials, there is no guarantee that BKM120, LEE011, BYL719 and LA-EP2006 will ever be commercially available anywhere in the world.
